Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationDepreciation & Amortization (IS)EBIATLeasesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables RefundsShares IssuedShares RepurchasedShort-Term Debt issuancesWages, Salaries and Other
Ratios

Amphastar Pharmaceuticals (AMPH) Leases: 2013-2025

Historic Leases for Amphastar Pharmaceuticals (AMPH) over the last 12 years, with Sep 2025 value amounting to $44.6 million.

  • Amphastar Pharmaceuticals' Leases rose 40.59% to $44.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $44.6 million, marking a year-over-year increase of 40.59%. This contributed to the annual value of $46.9 million for FY2024, which is 45.05% up from last year.
  • Amphastar Pharmaceuticals' Leases amounted to $44.6 million in Q3 2025, which was up 0.86% from $44.2 million recorded in Q2 2025.
  • In the past 5 years, Amphastar Pharmaceuticals' Leases registered a high of $46.9 million during Q4 2024, and its lowest value of $19.3 million during Q1 2021.
  • For the 3-year period, Amphastar Pharmaceuticals' Leases averaged around $35.8 million, with its median value being $32.3 million (2023).
  • As far as peak fluctuations go, Amphastar Pharmaceuticals' Leases surged by 59.01% in 2021, and later dropped by 7.33% in 2023.
  • Over the past 5 years, Amphastar Pharmaceuticals' Leases (Quarterly) stood at $26.9 million in 2021, then declined by 4.98% to $25.6 million in 2022, then rose by 26.53% to $32.3 million in 2023, then skyrocketed by 45.05% to $46.9 million in 2024, then surged by 40.59% to $44.6 million in 2025.
  • Its Leases was $44.6 million in Q3 2025, compared to $44.2 million in Q2 2025 and $45.8 million in Q1 2025.